Content area

Abstract

Recursion Pharmaceuticals Inc (RXRX) - Medical Equipment - Deals and Alliances Profile

Recursion Pharmaceuticals Inc (Recursion) is a clinical-stage biotech company that utilizes artificial intelligence and data-driven approaches to enhance drug discovery and development. The company pipeline products include CDK7 for advanced solid tumors; RBM39 for biomarker-enriched solid tumors and lymphoma; MALT1 for B-cell malignancies, LSD1 for small-cell lung cancer; PI3Ka H1047R for breast cancer; and ENPP1 for hypophosphatasia. Recursion's products are primarily aimed at healthcare providers and researchers in the pharmaceutical and biotechnology industries. The company operates through subsidiaries in Canada, the US and the UK.

Recursion Pharmaceuticals Inc (RXRX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

Details

1007133
Company / organization
Title
Recursion Pharmaceuticals Inc (RXRX)
Publication title
Number of pages
54
Publication year
2025
Publication date
2025
Publisher
GlobalData plc
Place of publication
London
Country of publication
United Kingdom
Publication subject
Source type
Report
Language of publication
English
Document type
Company Report
Document feature
Mergers & acquisitions
ProQuest document ID
3040264653
Document URL
https://www.proquest.com/reports/recursion-pharmaceuticals-inc-rxrx/docview/3040264653/se-2?accountid=208611
Copyright
Copyright GlobalData plc 2025
Last updated
2025-11-14
Database
ProQuest One Academic